The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Zyban 150 mg prolonged release tablets

Originalis B.V.PPA2306/005/001

Main Information

Trade NameZyban 150 mg prolonged release tablets
Active SubstancesBupropion hydrochloride
Dosage FormProlonged-release tablet
Licence HolderOriginalis B.V.
Licence NumberPPA2306/005/001

Group Information

ATC CodeN06AX12 bupropion


License statusAuthorised
Licence Issued21/12/2018
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusUnknown


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back